Does P Gp Inhibitors Oral Interact with Relugolix?
CDI records a major classification for P Gp Inhibitors Oral and Relugolix. The stored summary is: Co-administration increases relugolix exposure and risk of adverse reactions. If unavoidable, separate dosing by at least 6 hours and monitor frequently. The mechanism involves relugolix is a p-gp substrate; p-gp inhibition increases relugolix exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Relugolix Class
- Gonadotropin Releasing Hormone Receptor Antagonist
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Relugolix is a P-gp substrate; P-gp inhibition increases relugolix exposure
What To Tell Your Doctor or Pharmacist
If you are taking P Gp Inhibitors Oral and your doctor is considering prescribing Relugolix (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider